A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama

Fatimah S Dawood, Jorge Jara, Rosalba Gonzalez, Juan Miguel Castillo, Tirza De León, Dora Estripeaut, Kathia Luciani, Yarisa Sujey Brizuela, Alfredo Barahona, Rafael Antonio Cazares, Aracelis M Lawson, Mariana Rodriguez, Dinora de Viana, Danilo Franco, Marlene Castillo, Alicia M Fry, Larisa Gubareva, Daisuke Tamura, Michael Hughes, Paul GargiulloWilfrido Clara, Eduardo Azziz-Baumgartner, Marc-Alain Widdowson

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Oseltamivir reduces symptom duration among children with uncomplicated influenza, but few data exist on treatment efficacy and tolerability among hospitalized children, particularly among infants aged <1 year. We evaluated tolerability and efficacy of oseltamivir treatment of children aged 0-9 years hospitalized with influenza.

METHODS: We conducted a double-blind, randomized, placebo-controlled trial at tertiary care hospitals in El Salvador and Panama. Primary outcomes were length of hospitalization and increased work of breathing. Children were eligible if hospitalized <7 days after symptom onset with cough or sore throat plus tachypnea. Children were randomized 1:1 to receive oseltamivir or placebo; had swabs collected at enrollment for influenza RT-PCR testing; were assessed at enrollment and every 12 h for work of breathing; and were followed for adverse events through 7 days after discharge. Analyses were intention-to-treat.

RESULTS: Overall, 683 children were randomized (oseltamivir, n = 341, placebo n = 342). Fifty-three percent were aged <1 year and 30 had influenza (oseltamivir, n = 19; placebo, n = 11). The study was terminated early after enrollment of 21% of the sample size due to lower than anticipated participant accrual. Using Kaplan-Meier analysis, there was no significant difference in median length of hospitalization (3 days, IQR 2-4 vs. 5 days, IQR 3-7, p = 0.22) and increased work of breathing (36 h, IQR 24-72 vs. 96 h, IQR 13-108, p = 0.14) between oseltamivir versus placebo recipients. There was no difference in adverse events between groups.

CONCLUSION: Oseltamivir treatment was well tolerated among hospitalized children, including among infants aged <1 year.

Original languageEnglish
JournalAntiviral Research
Volume133
Pages (from-to)85-94
Number of pages10
ISSN0166-3542
DOIs
Publication statusPublished - Sep-2016

Keywords

  • Antiviral Agents/administration & dosage
  • Child
  • Child, Preschool
  • Comorbidity
  • El Salvador
  • Female
  • Hospitalization
  • Humans
  • Infant
  • Infant, Newborn
  • Influenza, Human/diagnosis
  • Length of Stay
  • Male
  • Oseltamivir/administration & dosage
  • Panama
  • Severity of Illness Index
  • Treatment Outcome

Fingerprint Dive into the research topics of 'A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama'. Together they form a unique fingerprint.

Cite this